28 September 2021 - This study, which was conducted as part of a project for revision of the pharmacoeconomic guideline, reviewed utility values used in the pharmacoeconomic submissions processed at HIRA during 2014–2018 to identify aspects of the current guidelines that may need to be revisited.
A total of 50 pharmacoeconomic submissions were processed at HIRA over the 5 years.